Aura Biosciences AURA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Aura Biosciences (AURA) Business Model and Operations Summary
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Key Insights
Aura Biosciences (AURA) Core Market Data and Business Metrics
Latest Closing Price
$5.86Market Cap
$371.41 MillionAverage Trade Volume
298,270 SharesTotal Outstanding Shares
62 Million SharesCEO
Dr. Elisabet de los Pinos Ph.D.Total Employees
106IPO Date
October 29, 2021SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
80 Guest Street, Boston, MA, 02135
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|